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Abstract: The etiopathogenesis of Inflammatory bowel disease (IBD) is a result of a complex
interaction between host immune response, the gut microbiome and environmental factors, such as
diet. Although scientific advances, with the use of biological medications, have revolutionized
IBD treatment, the challenge for maintaining clinical remission and delaying clinical relapse is still
present. As exclusive enteral nutrition has become a well-established treatment for the induction of
remission in pediatric Crohn’s disease, the scientific interest regarding diet in IBD is now focused on
the development of follow-on dietary strategies, which aim to suppress colonic inflammation and
delay a disease flare. The objective of this review is to present an extensive overview of the dietary
strategies, which have been used in the literature to maintain clinical remission in both Crohn’s
disease and Ulcerative colitis, and the evidence surrounding the association of dietary components
with clinical relapse. We also aim to provide study-related recommendations to be encompassed in
future research studies aiming to investigate the role of diet during remission periods in IBD.
Keywords: inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; dietary therapy;
maintenance enteral nutrition; dietary triggers; clinical relapse
1. Introduction
Inflammatory bowel diseases (IBD) are chronic, relapsing and debilitating inflammatory disorders,
of which Crohn’s disease (CD) and Ulcerative colitis (UC) are the most common [1]. While UC involves
only superficial inflammation in the colon and rectum, CD can cause transmural, granulomatous
inflammation throughout the gastrointestinal tract, anywhere from mouth to anus. Indicative IBD
symptoms include diarrhea, abdominal pain, blood in stool, extra-intestinal manifestations, such as
arthritis and delays in growth and puberty in children. IBD prevalence is particularly high in
North America, central and northern Europe, including Scotland [2,3]. The rising IBD incidence in
newly-industrialized countries adopting a Western type lifestyle [4], serves as a prime example of the
significant contribution of environmental factors and especially diet to IBD etiopathogenesis.
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Although the complete etiology of IBD remains to be fully understood, the prevailing paradigm
suggests a multifaceted interaction between an aberrant immune response and environmental stimuli,
mediated through the gut microbiome, in genetically susceptible people. Patients with CD have a
distinct, “dysbiotic” gut microbiome profile, compared to healthy people, characterized by lower
gut bacterial α diversity, and perhaps lower relative abundance of Faecalibacterium prausnitzii and
increased abundance of Escherichia coli [5,6]. The microbial composition differences which have been
observed between patients with CD and UC, potentially suggest that the observed microbial signature
is at least partially disease-specific [7]. So far, there is inconclusive and contradictory evidence on
whether changes in disease activity precede or follow shifts in the gut microbiome [5,8–10].
Several epidemiological studies suggest that a Mediterranean-type dietary pattern, comprising
mainly fiber-rich sources, such as fruit and vegetables, andω-3 fatty acid-rich food sources, is associated
with reduced risk of IBD development. Conversely, a Western-style diet, consisting mainly of
processed food, food additives, red meat and animal fat has been associated with increased
risk of IBD onset [11–14]. However, recent cohort studies have challenged these associations,
thus highlighting that epidemiological evidence, surrounding pre-illness dietary intake, and the
onset of IBD, is inconclusive [15,16].
The only well-established, evidence-based dietary therapy, used in CD, is exclusive enteral
nutrition (EEN). EEN consists of the exclusive consumption of a proprietary formula, typically for
6–8 weeks, and is the first-line treatment for induction of remission in mild and moderate pediatric CD
across Europe, Canada and Oceania [17,18]. Multiple lines of research, including systematic reviews,
meta-analyses and Cochrane reviews, have demonstrated the efficacy of EEN, particularly in children
with CD, with clinical remission rates at least comparable to those from corticosteroids [19–22]. While,
EEN efficacy has not yet been demonstrated consistently in adult populations, it is suggested that this
is partly a result of lower compliance, potentially derived from limited formula palatability and a lack
of established support mechanisms from the relevant clinical teams [23]. The role of EEN in UC has
not yet been extensively studied, and conclusions cannot be drawn regarding its efficacy [24].
Importantly, EEN is able to achieve higher intestinal mucosal healing rates than corticosteroids,
in children with CD [25,26]. As mucosal healing is assessed through invasive endoscopic procedures,
which are not always practical or ethically acceptable for research purposes, with a couple of notable
exceptions [26,27], various proxies have, thus, been used to assess the levels of intestinal inflammation.
Fecal calprotectin (FC), a neutrophil-derived protein, has emerged as a non-invasive predictor of
mucosal healing and is now established in the clinical setting. EEN has been shown to reduce FC
levels in pediatric populations by approximately 50% [28]. EEN, along with other forms of nutritional
support, such as total parenteral nutrition (TPN) have also been efficacious in reducing post-operative
occurrence in patients with CD undergoing surgery [29,30].
In addition to understanding the induction of remission, it is equally important to identify how
remission can be maintained by manipulating the diet. We recently demonstrated a rapid rise in FC
levels during the first 2–3 weeks of food reintroduction in children with EEN-induced remission [31].
Hence, the reintroduction of dietary constituents, when patients return to normal diet, is associated
with a rise in FC and with reactivation of intestinal inflammation. As patients frequently seek ways
to modify their diet to control their disease [32,33], identification of the putative causative dietary
components is arguably one of the most important priorities in CD research at present.
One of the main aims of both medical and nutritional treatments is to maintain clinical remission,
by suppressing immune response, thereby delaying a disease flare [34]. The most common maintenance
therapy in CD is the use of immunosuppressants, such as thiopurines or methotrexate. However,
the use of thiopurines has been associated with increased risk of adverse events (e.g., infection,
pancreatitis and rarely malignancy) [35–37]. Biologics are also increasingly used in up to 50% of
children with CD and while clearly efficacious, they are associated with loss of response over time, a
well-established side effect profile and high financial burden [38–40]. Additionally, relapse rates and
Nutrients 2020, 12, 2018 3 of 19
the need for surgery in IBD continue to be considerably high, thus, highlighting a therapeutic gap
where novel, non-medical therapies, such as nutritional therapies are needed.
The aim of this review was to provide a comprehensive overview of the evidence surrounding
dietary strategies for maintenance of remission in IBD, to explore potential dietary triggers of relapse,
and to conclude whether current evidence is sufficient to make dietary recommendations for use in
clinical practice. Furthermore, we aimed to provide a list with essential and desirable study-related
characteristics, which we believe, should form the basis of future research investigating the role of diet
in prolonging clinical remission in IBD.
2. Literature Review
An extensive literature search was undertaken on PubMed (inception to May 2020), including
Medical Subject Heading terms (“inflammatory bowel disease” OR IBD OR Crohn OR colitis) AND
(diet OR diet* OR nutrition OR nutr* OR food OR “enteral nutrition” OR polymeric OR elemental).
18,924 records were identified. Eligible studies included intervention and cohort studies investigating
the role of diet for the maintenance of clinical remission in both adult and pediatric IBD populations
in remission. Animal, in vitro and studies not in English were excluded. We also excluded studies
assessing dietary strategies for the induction of remission or perioperative nutritional support,
single-nutrient supplement studies, and observational studies associating pre-illness diet with the
onset of IBD. After full-text review of 226 articles, 39 studies fulfilled the eligibility criteria. In addition,
five studies were identified after cross-checking reference lists from the included papers, subsequently
resulting in a final inclusion of 44 studies. Comprehensive evidence tables presenting the included
studies and relevant information are displayed in Supplementary file 1.
We first present studies examining the efficacy of food reintroduction protocols in patients with
CD, after induction of remission using nutritional therapies. Subsequently, we focus on studies
employing enteral nutrition as a maintenance regime in patients with CD, and on studies using
ordinary food-based diets for maintenance of clinical remission in both CD and UC. Finally, we present
the current evidence on prospective, observational studies exploring the associations with dietary
components and risk of relapse in CD and UC.
2.1. Food Reintroduction Protocols in CD
Six intervention trials (three randomized controlled trials (RCT) and three non-randomized),
and two retrospective studies assessing food reintroduction protocols in 422 patients with CD were
included. Six studies recruited only adults [41–46], one recruited only children [47] and another had a
mixed population [48]. EEN was the most common induction treatment with some studies also using
TPN and exclusion diets [41,42,44]. Table 1 presents a summary of the food reintroduction protocols
used in studies which included a control group.
2.1.1. Symptom-Alleviating Exclusion Diets
Gradual, single-food reintroduction with exclusion of symptom-aggravating foods was the most
commonly used food reintroduction protocol. Jones et al. [41] demonstrated in an RCT that adherence
to a symptom-alleviating, food reintroduction diet, resulted in 70% lower clinical relapse rates, assessed
by disease activity indices, compared to patients following an unrestricted, fiber-rich diet (intervention:
30% vs. control: 100%, p < 0.05). Erythrocyte sedimentation rate (ESR) levels significantly decreased in
patients following the exclusion diet, whereas there was no change in the control group. Subsequently,
the same research group demonstrated in an uncontrolled trial that patients adhering to exclusion
diets had 36% clinical relapse rates after a 12-month follow-up [42]. Riordan et al. [46] showed that
patients following a symptom-guided exclusion diet after EEN-induced remission, had marginally,
but significantly lower 2-year clinical relapse rates than patients who were administered tapering
corticosteroids doses and followed general dietary advice (62% versus 79%, p = 0.048).
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The efficacy of symptom-guided exclusion diets, following EEN, was assessed in two uncontrolled
trials, which used double-blind food challenge tests [43,48]. No difference in clinical relapse rates were
observed between patients who followed exclusion diets, compared to those who followed unrestricted
diets in the first trial [43]. Similarly, duration of remission did not significantly differ between patients
with positive food challenges against those who did not identify symptom-triggering foods in the
second trial [48]. Some of the most frequently reported symptom-triggering foods in the above studies
were wheat, dairy products, eggs, and yeast-containing products.
2.1.2. Immunoglobulin G Exclusion Diet
Delayed onset of symptoms after food challenges, and the presence of subclinical inflammation
in asymptomatic patients, are two disadvantages of relying on symptom-guided elimination diets.
Wang et al. [45] aimed to address these limitations by using Immunoglobulin G (IgG) exclusion diets,
since high IgG and particularly IgG4 levels might be associated with an abnormal immune reaction to
those foods [49]. However, current guidelines suggest that increased IgG4 concentration against food
stimuli is a physiological immune reaction representing chronic exposure of the host to specific foods,
rather than a food intolerance [50]. Patients in the intervention group excluded foods causing moderate
or strong immunoreactivity, based on IgG levels, after testing against 14 commonly consumed food
items [45]. No significant differences in relapse rates and endoscopic scores between the intervention
and the control group (unrestricted diet) were observed.
2.1.3. LOFFLEX Diet
Woolner et al. [44] tested the efficacy of a low-fat, low-fiber diet (LOFFLEX) in a non-randomized
trial, following induction of remission with EEN or TPN. The diet was initially followed for 2–4 weeks
and was followed by gradual reintroduction of non-symptom triggering foods. Patients in the
control group followed a standard symptom-alleviating, exclusion diet. No significant differences in
remission rates were observed between the two groups (LOFFLEX: 44% versus standard: 45%, p = not
significant [NS]).
2.1.4. Rapid Food Reintroduction Diet
Faiman et al. [47] investigated the efficacy of a rapid food reintroduction regime in a pediatric,
retrospective study. Patients in the rapid reintroduction arm followed a low-residue diet for three days
and were subsequently allowed to consume an unrestricted diet. There were no significant differences
in clinical relapse rates between patients in the rapid arm compared to those following a standard,
gradual food reintroduction protocol (rapid: 50% vs. standard: 47%, p = NS).
Summary
Among the food reintroduction protocols presented here, only exclusion diets which aimed to
prevent exacerbation of clinical disease activity and symptoms demonstrated some clinical efficacy.
However, one challenge with interpreting previous studies from an era when non-invasive biomarkers
of luminal inflammation, such as FC, were unavailable, and endoscopic assessment was not used,
is whether gut inflammation parallels symptomatic response. A symptomatic response does not
always match with improvements in gut inflammation and the same often applies with alterations in
blood inflammatory markers (e.g., C-reactive protein [CRP], ESR). Therefore, the efficacy of these diets
in controlling colonic inflammation needs to be demonstrated before they can be recommended as
food reintroduction protocols.
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2.2. Dietary Therapies for Maintenance of Clinical Remission in IBD
2.2.1. Maintenance Enteral Nutrition in CD
Maintenance enteral nutrition (MEN) describes the use of EN formula, that comprises a percentage
of the total calorific intake, for maintenance of clinical remission. Nineteen studies assessing the
use of MEN in CD were included (Supplementary file 1). Eight were intervention trials (four RCT,
four non-randomized) and 11 were cohort studies. Twelve studies recruited adults (n = 1076) and
seven recruited children (n = 392). A comparator group was included in 17/19 (89%) of the studies.
Out of the 16 studies which compared clinical relapse rates between patients using MEN and those that
did not, 9/16 (56%) of the studies demonstrated lower relapse rates in patients using MEN; 8/11 (73%)
in adults [51–58] and 1/5 (20%) in children [59]. Conversely, in 3/11 (27%) adult and 3/5 (60%) pediatric
studies, clinical relapse rates did not differ between patients using MEN against those in the comparator
group [31,60–64]. In one pediatric study, MEN use led to lower relapse rates only in patients not using
any concomitant medication, with no significant differences observed in relapse rates between patients
using MEN and azathioprine than those only using azathioprine [65].
Out of the 14 studies which had a comparator group and reported the amount of MEN used,
10/14 (71%) used MEN covering >35% of patients’ daily energy requirements and 4/14 (29%) used
MEN covering ≤35% (Figure 1). Consumption of >35% MEN was associated with significantly lower
relapse rates compared to the control group, in 8/10 (80%) studies. Conversely, in all four studies using
≤35% MEN, there was no additional benefit of MEN use in reducing clinical relapse. Median (Q1, Q3)
1-year clinical relapse rates were 28% (21, 37) amongst patients consuming >35% MEN and 59% (33, 86)
in patients consuming ≤35% MEN (Figure 1). In a retrospective, pediatric study, which did not report
relapse rates, patients consuming 50% MEN had similar duration of clinical remission compared to
those who did not consume MEN [63].Nutrients 2020, 12, x FOR PEER REVIEW 1 of 21 
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relapse rates in patients consuming MEN, based on amount of formula consumed (≤35%/>35% of 
energy requirements). 
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with CD. In the first RCT, 59% of patients adhering to a low-refined carbohydrate, fiber-rich diet 
relapsed within two years, compared to 64% of patients following a low-fiber diet (p = NS) [73]. In 
the second RCT, adherence to a low-carbohydrate diet was not significantly associated with higher 
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Semi-Vegetarian Diet 
Chiba et al. [75] investigated the efficacy of a plant-based, semi-vegetarian diet for maintenance 
of clinical remission in a non-randomized trial, in patients with CD, with medically (infliximab) or 
surgically induced remission. Details of the diet are presented in Table 1. Patients not adhering to the 
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additives, and high in monounsaturated and ω-3 fatty acids, in a double-blind RCT in patients with 
CD, only available as an abstract. None of the patients in the “anti-IBD” diet group relapsed after one 
year, compared to 6/19 (32%) patients receiving a fructooligosaccharide supplement along with 
normal diet (p < 0.05), and to 4/19 (21%) patients receiving placebo along with normal diet (p = NS). 
Figure 1. (A) Comparison of 1-year clinical relapse rates in patients using MEN against those who
did not use MEN in studies reporting the amount of MEN formula consumed (≤35%/>35% of energy
requirements). F indicates statistically significant differences in clinical relapse rates between MEN
group and control group in the total duration of each study. Dark colored bar charts indicate RCTs.
+ Clinical relapse rates in Esaki et al., 2006, Hirai et al., 2013 and Hirai et al., 2019 are approximate
numbers extracted from figures. ++ only 6-month relapse rates were available. (B) Median clinical
relapse rates in patients consuming MEN, based on amount of formula consumed (≤35%/>35% of
energy requirements).
Fifteen studies reported concomitant maintenance medication, with two studies stratifying patients
in two different groups depending on the use of MEN with/without additional medication [58,65].
The use of MEN was associated with significantly lower clinical relapse ates, compared to he absence
of MEN, in all three studies where aminosalicyl tes were t e main mai tenance treatment [53,56,66] and
in 2/3 (33%) studies where MEN was used as t e sole maint nance treatment [58,60,65]. Us of MEN
as an adjunctive therapy to steroids and/or immunosuppressants, was effective in reducing relapse
rates in 4/8 (50%) studies [54,58,59,67]. In 3/4 studies in which MEN was not effective in augmenting
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the efficacy of steroids or immunosuppressants, it was prescribed in low amounts (≤35% of energy
intake). Lastly, when infliximab was used as the main maintenance therapy, patients consuming MEN
had significantly lower relapse rates, compared to those not using MEN, in 1/3 studies (33%) [57].
However, a recent meta-analysis, which examined the effect of MEN as adjunctive treatment to anti-TNF
therapy in patients with both, active and inactive CD, showed that patients using MEN had increased
probability of achieving remission than those not using MEN (pooled OR (95%CI, 2.23 [1.60–3.10]) [68].
The type of MEN formula does not seem to affect clinical efficacy, as no significant differences
in clinical remission rates were observed between patients using polymeric compared to those using
elemental formulas, in an RCT of 33 adults (polymeric: 43% vs. elemental: 42%, p = NS) [67].
The use of MEN was associated with further clinical benefits: improved endoscopic indices,
reduced mucosal cytokine levels [55], reduction of FC during the early food reintroduction period [31]
and increased height [59] and weight z-scores [63] in children. The use of MEN, concomitantly with
a low-fat diet, has also been associated with a reduced risk of post-operative disease recurrence,
in patients undergoing surgical resection, compared to patients on a normal diet [69]. Interestingly,
in two pediatric studies, not included in the present review due to inclusion of patients with active
disease, intermittent use of EEN over one year, was associated with a significant reduction in annual
steroid use and increased growth velocity [70,71]. This EN regime could serve as an alternative in
patients who struggle to consume EN over a large period of time but would eventually require repeated
compliance to additional EEN courses in patients with EEN-induced remission.
Summary
It could be assumed that the main barrier for the wider use of MEN is low compliance, due to low
formula palatability and patients’ fatigue. Compliance was not assessed in studies in which MEN was
not efficacious [60,63,64]. Hence, treatment failure could have been a result of low acceptability rather
than limited MEN efficacy. Although an intake covering ≤35% of patients’ daily energy requirements is
not sufficient to exert beneficial outcomes on the disease trajectory, larger MEN intakes demonstrated
significant efficacy in maintaining clinical remission (Figure 1). Considering that immunosuppressants
are known to have a significant adverse event profile, MEN could potentially be a safer effective
alternative in some patients [72].
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Table 1. Summary of food reintroduction protocols and food-based dietary therapies which have been used as a strategy for maintenance of clinical remission in IBD
in studies which included a control group.
Dietary Regime Reference, Setting Cohort Included Dietary Components Excluded Dietary Components Control Group Clinical Efficacy(Disease Activity)
Clinical Efficacy
(FC/Endoscopy)
Food reintroduction protocols in CD
Symptom-alleviating food
reintroduction diets
Jones et al., 1985 [41], UK CD Personalized diet: single, daily food reintroduction Symptom-triggering foods (most common:wheat, dairy, vegetables) Unrestricted diet
√
NR
Riordan et al., 1993 [46],
UK CD Personalized diet: single, daily food reintroduction
Symptom-triggering foods (most common:
corn, wheat, milk, yeast) Unrestricted diet + corticosteroids
√
NR
LOFFLEX diet Woolner et al., 1998 [44],UK CD
Low-fat (~50 g/d) + low-fiber (~10 g/d) diet: lean
meat, fish, soy milk, rice, olive oil, ≤2 portions of
vegetables & fruit/day, refined sugars
Red meat, processed fish, dairy, most grains,
pulses, >2 dried portions of fruit and
vegetables/day, tea, coffee, nuts, alcohol, sauces
Gradual food reintroduction × NR
Rapid food reintroduction Faiman et al., 2014 [47],UK CD
Unrestricted diet following initial 3-day low-residue
diet post EEN completion
High-residue foods for 3 days post EEN
completion Gradual food reintroduction × NR
IgG exclusion diet Wang et al., 2017 [45],China CD
Personalized diet (foods not causing increased IgG
levels and symptoms)
Foods causing high IgG levels (most common:
rice, tomato, egg, maize) Unrestricted diet × ×
Food-based therapies in IBD
Low-refined carbohydrate
diet
Ritchie et al., 1987 [73],
UK CD
Low-refined, fiber-rich diet, consumption of only
unrefined carbohydrates Foods containing white flour and sugar
Low-fiber, no restriction in refined
carbohydrates × NR
Low-carbohydrate diet Lorenz-Meyer et al., 1996[74], Germany CD Carbohydrates <84 g/d, specific foods not reported NR Habitual diet × NR
Semi-vegetarian diet Chiba et al., 2010 [75],Japan CD
Daily: vegetables, fruit, miso, rice, legumes, yoghurt;
weekly: fish; fortnightly: meat
Cheese, bread, sweets, fast food, juices,
carbonated drinks Omnivorous diet
√
NR
Anti-IBD diet * Mutlu et al., 2016 [76],USA CD NR
Wheat and most other grains, animal fat,
additives, preservatives
Habitual diet + FOS supplement
Habitual diet + placebo
√
×
NR
NR
Low red & processed
meat diet
Albenberg et al., 2019 [77],
USA CD All except red & processed meat
Red & processed meat
(≤1 servings/month)
≥2 servings of red & processed meat
per week × ×
CDED + 25% MEN Levine et al., 2019 [78],Israel, Canada CD
MEN: 25% of energy requirements mandatory:
chicken, eggs, potatoes, banana, apple;
recommended: fruit & vegetables
Gluten, dairy products, red and processed
meat, food additives, coffee, alcohol Normal diet + 25% EN
√
×
Dairy-free diet Wright et al., 1965 [79],UK UC All except dairy products (butter allowed) All dairy products including cheese Exclusion of fried foods, condiments × NR
High-fiber diet Davies and Rhodes 1978[80], UK UC
Oat bran supplement (25 g/d), increased intake of
wholewheat cereals, vegetables NR Habitual diet × NR
Cow’s milk protein
elimination diet
Strisciuglio et al., 2013
[81], Italy UC All except dairy products All dairy products including cheese and butter Habitual diet × NR
Alberta-based
anti-inflammatory diet *
Keshteli et al., 2016 [82],
USA UC
Increased intake of prebiotics, soluble fiber,ω-3 fatty
acids Red and processed meat Normal diet × ?
Carrageenan-free diet Bhattacharyya et al., 2017[83], USA UC All except carrageenan-containing products
Products containing carrageenan (e.g., yogurt,
ice cream, processed meat, beer)
Same diet + carrageenan-containing
capsules
√
×
√
: Higher clinical efficacy signals, defined as significant improvement in disease activity indices, FC levels or endoscopic indices in the intervention diet group, compared to the
control group; ×: Equal/lower clinical efficacy signals in intervention diet group, compared to the control group; ?: Unclear evidence; NR: not reported; * only presented as an abstract.
CD: Crohn’s disease, CDED: Crohn’s disease exclusion diet, EN: Enteral nutrition, FC: Fecal calprotectin, FOS: fructooligosaccharides, IgG: Immunoglobulin G, IBD: Inflammatory bowel
diseases, MEN: Maintenance enteral nutrition, UC: Ulcerative colitis.
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2.2.2. Food-Based Therapies
Twelve trials (n = 1180) assessed the efficacy of food-based interventions for maintenance of
clinical remission [73–85]. Six included only patients with CD (five in adults, one in children) and
six only patients with UC (five in adults, one in children). Table 1 presents an overview of those
dietary strategies.
CD Studies
Low-Refined, Low-Carbohydrate Diets
One RCT investigated the efficacy of a low-refined carbohydrate diet and another focused on
reducing total carbohydrate intake [73,74] as a means of maintaining clinical remission in patients with
CD. In the first RCT, 59% of patients adhering to a low-refined carbohydrate, fiber-rich diet relapsed
within two years, compared to 64% of patients following a low-fiber diet (p = NS) [73]. In the second
RCT, adherence to a low-carbohydrate diet was not significantly associated with higher remission
rates, compared to a normal diet [74].
Semi-Vegetarian Diet
Chiba et al. [75] investigated the efficacy of a plant-based, semi-vegetarian diet for maintenance
of clinical remission in a non-randomized trial, in patients with CD, with medically (infliximab) or
surgically induced remission. Details of the diet are presented in Table 1. Patients not adhering to
the allowed/disallowed foods were assigned to an omnivorous diet group. Strikingly, all patients
in the intervention group maintained clinical remission after a one-year follow-up, with only 1/16
(16%) patients relapsing after two years, compared to 4/6 (67%) patients in the omnivorous diet group
(p < 0.001). Relapse was assessed as appearance of symptoms requiring medical care. In a subsequent
single-group trial, the same research group showed that patients with UC following the same dietary
protocol had 39% clinical relapse rates after five years [85].
Anti-IBD Diet
Mutlu et al. [76] assessed the effect of an “anti-IBD” diet, a diet low in animal fat, grains, additives,
and high in monounsaturated and ω-3 fatty acids, in a double-blind RCT in patients with CD,
only available as an abstract. None of the patients in the “anti-IBD” diet group relapsed after one year,
compared to 6/19 (32%) patients receiving a fructooligosaccharide supplement along with normal diet
(p < 0.05), and to 4/19 (21%) patients receiving placebo along with normal diet (p = NS). Furthermore,
a significant increase in the abundance of bacteria from the genus Roseburia was observed in the
“anti-IBD” diet group.
Low Red and Processed Meat Diet
Albenberg et al. [77] assessed the effect of red and processed meat consumption on relapse risk in
patients with CD, in a well-designed RCT. Patients in the intervention group were allowed consumption
of no more than one serving of red and processed meat per month, and those in the control group were
instructed to consume at least two portions per week. Clinical relapse rates and FC concentration did
not significantly differ between the two groups, after a follow-up of 49 weeks.
Crohn’s Disease Exclusion Diet
In a recent RCT, Levine et al. [78] assessed the efficacy of the CD exclusion diet (CDED) with
partial enteral nutrition for induction and maintenance of clinical remission in CD. CDED is a diet
which excludes foods hypothesized to aggravate intestinal permeability, induce dysbiosis and colonic
inflammation (Table 1). After induction of remission with 50% CDED and 50% EN, patients were
instructed to consume 75% of their energy requirements through CDED and 25% through EN. Patients
in the control group consumed a normal diet with 25% MEN. After six weeks, 28/32 (88%) of patients
following CDED were still in clinical remission, compared to 14/25 (56%) in the control group (p < 0.05).
Of note, FC levels reduced in the intervention but, this was not statistically significant (FC, µg/g, mean;
CDED: baseline: 1744 vs. follow-up: 732, p = 0.22; control: baseline: 1021 vs. follow-up: 1589, p = 0.36).
Although patients in the CDED group consumed only a small amount of MEN, it remains difficult to
fully disentangle the extent to which the continued intake of MEN contributed to higher remission
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rates. Although changes in the composition of the gut microbiome were similar during the induction
of remission between the two groups, there was a rebound in the relative abundance of Proteobacteria
in the control group during the maintenance phase, compared to a sustained reduction in the CDED +
MEN group. Clostridia continued to be higher in both groups, whereas there was a small rebound in
Actinobacteria in both groups, compared to the beginning of treatment. Shannon diversity did not
significantly change in any of the two groups.
UC Studies
Dairy-Free Diets
Lactose is a dietary component that has been implicated in UC, with dairy products being
frequently excluded among patients [86]. Wright et al. [79] showed in a RCT that 1-year clinical relapse
rates were not significantly different between patients with UC following a dairy-free diet compared to
patients on a normal diet (dairy-free: 62% vs. normal: 78%, p = NS). Similarly, in another RCT, children
with UC following a cow’s milk protein elimination diet had similar clinical relapse rates compared to
children on a normal diet (intervention: 54% vs. control: 53%, p = 1) [81].
High-Fiber Diet
Contrary to the prevailing notion of the beneficial properties of fiber, the results from an
uncontrolled trial in patients with UC showed that high fiber intake, particularly in the form of oat bran,
may result in worse outcomes [80]. Sulfasalazine was the main maintenance therapy, with patients
adhering to the high-fiber diet being advised to discontinue sulfasalazine two weeks after the start of the
intervention. After a one-year follow-up, 75% of patients in the high-fiber group relapsed, compared to
20% in the normal diet group, suggesting exacerbation of disease activity due to high fiber consumption
and/or discontinuation of sulfasalazine. Evidence from a systematic review on supplementation studies
showed that fiber supplementation was not effective in maintaining clinical remission in CD [87].
However, supplementation with Plantago ovata, a fermentable fiber, was associated with lower relapse
risk in patients with inactive UC, with the authors suggesting that this resulted from an increased
production of butyrate [88]. This emphasizes that the role of fiber in IBD has not been fully understood
and might differ between CD and UC.
Anti-Inflammatory Diet
Another exclusion diet assessed in an RCT in patients with UC, only available as an abstract,
was the “Alberta-based anti-inflammatory diet” [82], which limited red meat and recommended
consumption of pre- and probiotics, soluble fiber andω-3 fatty acids. No significant differences were
observed in the relapse rates between patients following the exclusion diet and patients in the control
group following general dietary advice. However, the levels of FC decreased by almost 50% in the
intervention group and underwent a threefold increase in the control.
Carrageenan-Free Diet
The effect of a carrageenan-free diet on relapse rates in patients with UC was assessed in a pilot,
double-blind RCT [83]. Carrageenan is a widely used food additive, causing colonic inflammation in
animal models of colitis [89]. Patients in both groups followed a carrageenan-free diet, with those in
the intervention group consuming placebo, and those in the control group, carrageenan-containing
capsules. Three patients dropped out in the intervention group. Relapse rates, assessed with disease
activity indices or need for escalation of treatment, were significantly lower in the intervention than
the control group, after one year, in per-protocol analysis (intervention: 0/7 [0%] vs. control: 3/6 [50%]),
p = 0.046). FC levels did not significantly change in any group (FC, mg/g, mean ± SD; intervention:
baseline: 149 ± 112 vs. follow-up: 111 ± 91, p = NS; control: baseline: 133 ± 125 vs. follow-up: 171 ±
143, p = 0.06).
Summary
Out of all the different food-based strategies explored in the present review, CDED + MEN,
the semi-vegetarian diet and the carrageenan-free diet demonstrated signals of efficacy in maintaining
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clinical remission. However, these signals were mostly associated with maintenance of clinical
disease activity and symptomatic improvement, rather than control of gut-specific inflammation.
These presumptive dietary therapies should be further studied in larger, multicenter RCTs and their
efficacy should be confirmed using objective colonic inflammation or endoscopic markers, before strong,
clinical recommendations can be made. The common feature of these three diets is the restriction
of food additives. However, in the CDED protocol, food additives are not completely eliminated
since EN formulas are heavily industrialized and abundant in food additives (i.e., maltodextrin) [19].
Due to food industrialization, the exposure of patients to emulsifiers and other food additives has
increased [90]. Animal studies and in vitro experiments have shown that exposure to carrageenan,
maltodextrin, polysorbates and carboxymethyl cellulose may have detrimental effects on gut health [78].
However, the translation of findings from animal experiments to human CD is required before any
dietary recommendations can be made. A recent analysis of 61 different EEN formulas, used for the
induction of remission in CD, demonstrated no significant differences in remission rates between
patients consuming EEN formulas containing at least one food additive implicated in IBD pathogenesis,
compared with patients who consumed EEN formulas that did not contain those food additives,
highlighting that the role of food additives in IBD has not yet been elucidated [19].
Current evidence regarding the rest of the food-based therapies assessed in the present review did
not demonstrate their efficacy for maintenance of clinical remission in IBD. Although both the anti-IBD
and the anti-inflammatory diet showed initial signals of efficacy, conclusions cannot be made unless
the full peer-reviewed publications are available. Among other diets anecdotally reported in IBD,
are diets low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP),
mostly recommended for the management of irritable bowel syndrome (IBS). Since IBS-like symptoms
are regularly reported in IBD, patients might receive some symptom relief by following low-FODMAP
diets [91,92]. However, there is no scientific evidence that these diets are effective for controlling
colonic inflammation and maintaining clinical remission, neither in patients with CD nor UC.
2.3. Diet and Risk of Relapse: Epidemiological Evidence
Five prospective, observational studies (n = 2463 adults) investigating the association of diet with
relapse risk were identified. Two trials had UC-only cohorts [93,94], one a CD-only cohort [95] and
two studies recruited patients with both conditions [96,97]. Dietary assessment was performed only at
baseline with the use of food frequency questionnaires [93,94,97], a dietary screener questionnaire [96]
or a dietary history questionnaire [95].
Dietary temperance, assessed by a single question, about how much patients restricted their
habitual diet (strong temperance: very frequent avoidance of foods) was associated against relapse risk
in 76 patients with CD [95]. Moderate dietary temperance was negatively associated with time to relapse,
suggesting that patients who occasionally consumed foods of their preference, took longer to relapse
compared to those who rarely excluded foods. A high ratio ofω-6/ω-3 fatty acids was associated with
a 46% lower risk of relapse. However, high CRP levels, the presence of past surgery and corticosteroid
usage were also significantly positively associated with time to relapse, thereby potentially masking
the true contribution of dietary factors on relapse risk.
The association of fiber intake and relapse risk was examined in two studies, which provided
contradicting results [96,97]. Intakes of fiber and whole grain foods in the highest quartile were
associated with 42% and 37% lower risk of relapse in 1130 patients with CD, compared to intakes in the
lowest tertile, after multivariate adjustment [96]. No significant associations were observed in patients
with UC. Conversely, in another study, high fiber intake, was positively associated with increased
relapse risk, in 165 patients with IBD (OR [95%CI]: 3.65 [1.44–9.26]) [97]. The results were not adjusted
for disease characteristics and were not reported separately for patients with CD and UC.
In a multi-center study, Barnes et al. [94] associated the intake of specific fatty acids, processed meat
and alcohol with relapse rates. Patients with an intake of myristic acid in the third tertile, were more
likely to relapse, compared to those on the first tertile, after multivariate adjustment (OR [95% CI]: 3.01
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[1.17–7.74]). There were no significant associations between the consumption of processed meat and
alcohol with the risk of relapse. Conversely, Jowett et al. [93] showed that patients with UC reporting
a high intake (third tertile) of protein, meat and especially red meat, had increased risk of disease
relapse compared to patients with a lower intake (first tertile), after multivariate adjustment (red and
processed meat, OR [95%CI]): 5.19 [2.09–12.9]). The authors suggested that their findings could be
attributed to sulfur, a dietary component, which has been associated with an endoscopically active
disease phenotype [98].
Summary
In all studies, diet was assessed once at baseline, and therefore may not be representative of
the diet at follow-up, when disease activity was assessed. Overall, the epidemiological evidence
investigating the association of dietary components with disease recurrence is considerably limited and
somewhat contradictive and inconclusive, highlighting the need for further, well-designed studies.
3. Future Directions
The compelling efficacy of EEN in ameliorating active disease in pediatric CD highlights the
importance of diet in the management of IBD. There is remarkable ongoing research activity surrounding
food-based treatments in active IBD, with the specific carbohydrate diet, the CD treatment with eating
(CD-TREAT) diet, CDED and the autoimmune protocol diet, being some prime examples [78,99–101].
CD-TREAT, a novel food-based diet, designed to replicate the nutritional composition of EEN, has shown
promising clinical efficacy in a pilot trial in patients with active CD [99]. The prevailing paradigm
regarding the mechanism of action of CD-TREAT is similar to that of EEN, since the modulation of the
gut microbiome has been linked to both dietary therapies [5,99].
Although the scope of our review focuses on food-based dietary therapies, it is worth mentioning
that there is a plethora of various dietary components that are not discussed in detail here, and which
could play a role in controlling disease activity or gut symptoms in patients with IBD in remission [102].
Indicative examples include single-nutrient supplements, such as vitamin D, ω-3 fatty acids and zinc,
nutritional components, such as flavonoids, bioactive compounds (e.g., curcumin), prebiotics and other
non-nutritional compounds, such as probiotics and short chain fatty acids [103]. More information
about these dietary components can be found in comprehensive, recently published reviews [102,103].
Although MEN consumption seems a promising strategy for disease maintenance in CD, long-term
adherence may be challenging for some patients [104]. Hence, there is an unmet need to identify
the exact dietary components triggering disease activity and develop sustainable, long-term dietary
strategies based on the exclusion of these components. We propose several essential and desirable
features that we believe should be incorporated in the design of trials investigating dietary therapies
for maintenance of clinical remission and observational studies, aiming to identify dietary triggers of
relapse in IBD (Table 2).
Trials investigating strategies for maintenance of clinical remission should have an RCT design,
be adequately powered, and ideally involve multiple recruitment centers (Table 2). Pilot, uncontrolled
studies are important to test early efficacy signals and the feasibility of an intervention. Cohort studies
should employ a prospective design to minimize the potential bias of reverse causation (Table 2).
Long-term follow-up, which would allow an adequate number of endpoints and a representative
sample size are essential characteristics. Since CD and UC have different disease phenotypes, both
intervention and cohort studies should include homogeneous populations. When not feasible,
stratification according to disease phenotype is required during statistical analysis.
Outcomes of remission and relapse should be defined using a combination of routinely applied
clinical disease activity indices and objective biomarkers of systemic (e.g., ESR, CRP) and intestinal
inflammation (e.g., FC). Once more, the difference between symptom response and objective markers
of luminal disease activity is important in distinguishing between nutritional strategies aimed at
prevention of symptom recurrence versus avoidance of relapse. While, this may seem cumbersome
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to labor the point, clarifying this distinction as objectively as possible, will be essential in moving
nutritional research forward in IBD.
As patients will most likely be on concomitant maintenance treatment with other drugs at the
time of recruitment, stratification based on maintenance medication is recommended. Adjustment
for covariates, which might influence the outcome of interest should be performed during statistical
analysis to minimize bias in exploring associations between dietary components and risk of relapse.
For studies evaluating food reintroduction protocols, we recommend, if possible, the collection of
multiple, serial fecal samples (recognizing the practical issues around this). This will help to best
associate dynamic changes in the gut microbiome, with short-term changes in dietary intake [105].
The assessment of dietary compliance and overall dietary habits holds pivotal importance and
should be performed in every study. Dietary assessment should be performed both, at baseline and
at the end of the follow-up period and ideally multiple times throughout the observational period.
This would assess the uniformity of the dietary pattern throughout the study period and provide a
better representation of the association between diet and the disease outcome. New technologies,
such as web-based applications for dietary assessment may be incorporated. However, these must
first be validated within the target populations. Up-to-date food composition tables incorporating
complete dietary information should be used and the intake of food groups, food additives and dietary
patterns should be analyzed, in addition to that of nutrients. As new molecular-based techniques are
becoming available, the use of blood or fecal metabolites as food biomarkers could be incorporated as
a complementary method to conventional dietary assessment.
Table 2. Essential and desirable characteristics of intervention trials aiming to assess the efficacy of
dietary strategies for the maintenance of clinical remission and cohort studies aiming to investigate the
association of dietary components with the risk of relapse in patients with IBD.
Essential Characteristics Trials Cohort Studies
Randomized controlled design
√
n/a
Prospective cohort design n/a
√
Large, representative sample
√ √
Long-term follow-up suitable for identification of adequate number of clinical relapses
√ √
Separate analysis for UC and CD cohorts
√ √
Definition of remission and relapse outcomes using disease activity indices and objective biomarkers of
systemic (e.g., CRP, ESR) and intestinal
(e.g., FC) inflammation
√ √
Adjustment for use of maintenance drugs and other covariates
√ √
Dietary assessment
√ √
Analysis of nutrients, food groups and food patterns
√ √
Use of up-to-date, complete food composition tables for dietary analysis
√ √
Assessment of mechanism underlying the mode of action of diet
(e.g., metabolome, microbiome, immune profile)
√ √
Desirable characteristics
Multicenter design
√ √
Homogeneous population (only CD/only UC)
√ √
Endoscopic assessment
√ √
Use of novel technologies for dietary assessment
(e.g., web-based tools)
√ √
Analysis of other dietary components (e.g., gluten) and non-nutrient components (e.g., food additives)
√ √
Incorporation of food biomarkers in dietary assessment
(e.g., plasma/fecal metabolites)
√ √
Collection of serial fecal samples during early food reintroduction to assess dynamic changes in gut
microbiome
√ √
Dietary assessment at multiple timepoints throughout the study to assess uniformity of dietary habits
√ √
√
: Higher clinical efficacy signals, defined as significant improvement in disease activity indices, FC levels
or endoscopic indices in the intervention diet group, compared to the control group; CD: Crohn’s disease,
CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, FC: Fecal calprotectin, n/a: not applicable, UC:
Ulcerative colitis.
To our knowledge, among the included studies using food-based therapies for maintenance of
remission in IBD, the assessment of the gut microbiome was only performed in the trials by Levine
et al. [78] and Mutlu et al. [76]. This highlights a gap in the characterization of the mechanism
of action in studies assessing food-based therapies. With the rapid advance of high-throughput
profiling, examination of the gut microbiome and the immune system has now become more feasible.
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Therefore, it should be an integral part of every dietary study in IBD, aiming to understand underlying
mechanisms by which diet provokes inflammatory response and the mediating role of the gut
microbiome [106]. Along with novel nutritional therapies, microbial therapeutics could also serve as
a potential paradigm-changing strategy for the management of IBD, which could complement the
established medical treatment and form a triad, to improve disease management and quality of life of
patients with IBD.
4. Conclusions
There are compelling reasons to believe that specific dietary triggers of gut inflammation in
IBD exist and can be identified. Therefore, an urgent need exists to design high-quality dietary
studies, in order to both mobilize diet as a therapy, and simultaneously unravel these triggers and
their mechanisms of action in driving disease pathology. Such an approach would likely lead to
reduced treatment costs and provide new insights into the disease itself. The onset of multiple ’omics
technologies and computational tools in recent years, means we are now capable to advance our
knowledge in the area of nutritional research even further, understand the complex interplay between
diet, the host and the gut microbiome and develop personalized dietary treatment options to control
disease activity.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/7/2018/s1,
File S1: Summary of studies investigating the role of diet for maintenance of clinical remission in IBD.
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